valproic acid has been researched along with Alloxan Diabetes in 14 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of hyperglycemia on the pharmacokinetics of valproic acid (VPA) were examined by time-concentration profiles of plasma VPA accompanied with blood glucose (BG) changing." | 7.80 | The effect of hyperglycemia on the pharmacokinetics of valproic acid studied by high-performance liquid chromatography with electrochemical detection. ( Hakamata, H; Ishii, N; Kotani, A; Kotani, T; Kusu, F, 2014) |
| "We investigated the therapeutic effects of valproic acid (VPA) on erectile dysfunction and reducing penile fibrosis in streptozocin (STZ)-induced diabetic rats." | 3.83 | Antifibrogenic role of valproic acid in streptozotocin induced diabetic rat penis. ( Bayraktar, C; Eren, H; Gurgen, SG; Karaguzel, E; Kazaz, IO; Kutlu, O; Kutlu, S; Okatan, AE, 2016) |
| "The effects of hyperglycemia on the pharmacokinetics of valproic acid (VPA) were examined by time-concentration profiles of plasma VPA accompanied with blood glucose (BG) changing." | 3.80 | The effect of hyperglycemia on the pharmacokinetics of valproic acid studied by high-performance liquid chromatography with electrochemical detection. ( Hakamata, H; Ishii, N; Kotani, A; Kotani, T; Kusu, F, 2014) |
| "Valproic acid has been shown to upregulate estrogen receptors (ERs) in breast and prostate cancer tissues." | 1.48 | Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors. ( Bhadada, S; Dudhrejiya, A; Patel, B; Rabadiya, S; Vaishnav, D, 2018) |
| " Chronic administration of valproate seems to have beneficial effects on diabetic neuropathy." | 1.48 | Sodium valproate ameliorates memory impairment and reduces the elevated levels of apoptotic caspases in the hippocampus of diabetic mice. ( Amirpour-Najafabadi, B; Gholami, M; Hosseini, S; Sadegh, M; Zareie, P, 2018) |
| "Valproic acid (VPA) is a first-line drug used for the treatment of epilepsy and migraine as well as established as a HDAC inhibitor." | 1.42 | Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat. ( Jena, G; Khan, S; Tikoo, K, 2015) |
| " The treatment was started on the 5th day after STZ injection with the same dose as in group II and it was considered as 1st day of treatment with gold nanoparticles for 7 days to each rat of (group IV) treated autistic diabetic group(TAD) at a dosage of 2." | 1.42 | Pancreatic response to gold nanoparticles includes decrease of oxidative stress and inflammation in autistic diabetic model. ( Abd-Elhakim, YM; Al-Ayadhi, LY; Selim, ME, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Coughlan, MT | 3 |
| Ziemann, M | 3 |
| Laskowski, A | 3 |
| Woodruff, TM | 3 |
| Tan, SM | 3 |
| Axelsson, AS | 1 |
| Mahdi, T | 1 |
| Nenonen, HA | 1 |
| Singh, T | 1 |
| Hänzelmann, S | 1 |
| Wendt, A | 1 |
| Bagge, A | 1 |
| Reinbothe, TM | 1 |
| Millstein, J | 1 |
| Yang, X | 1 |
| Zhang, B | 1 |
| Gusmao, EG | 1 |
| Shu, L | 1 |
| Szabat, M | 1 |
| Tang, Y | 1 |
| Wang, J | 1 |
| Salö, S | 1 |
| Eliasson, L | 1 |
| Artner, I | 1 |
| Fex, M | 1 |
| Johnson, JD | 1 |
| Wollheim, CB | 1 |
| Derry, JMJ | 1 |
| Mecham, B | 1 |
| Spégel, P | 1 |
| Mulder, H | 1 |
| Costa, IG | 1 |
| Zhang, E | 1 |
| Rosengren, AH | 1 |
| Rabadiya, S | 1 |
| Bhadada, S | 1 |
| Dudhrejiya, A | 1 |
| Vaishnav, D | 1 |
| Patel, B | 1 |
| Patel, MM | 1 |
| Patel, BM | 2 |
| Zareie, P | 1 |
| Gholami, M | 1 |
| Amirpour-Najafabadi, B | 1 |
| Hosseini, S | 1 |
| Sadegh, M | 1 |
| Raghunathan, S | 1 |
| Porwal, U | 1 |
| Kotani, A | 1 |
| Kotani, T | 1 |
| Ishii, N | 1 |
| Hakamata, H | 1 |
| Kusu, F | 1 |
| Khan, S | 3 |
| Jena, G | 3 |
| Tikoo, K | 1 |
| Selim, ME | 1 |
| Abd-Elhakim, YM | 1 |
| Al-Ayadhi, LY | 1 |
| Akindele, AJ | 1 |
| Otuguor, E | 1 |
| Singh, D | 1 |
| Ota, D | 1 |
| Benebo, AS | 1 |
| Kutlu, O | 1 |
| Karaguzel, E | 1 |
| Gurgen, SG | 1 |
| Okatan, AE | 1 |
| Kutlu, S | 1 |
| Bayraktar, C | 1 |
| Kazaz, IO | 1 |
| Eren, H | 1 |
| Kumar, S | 1 |
| Noh, H | 1 |
| Oh, EY | 1 |
| Seo, JY | 1 |
| Yu, MR | 1 |
| Kim, YO | 1 |
| Ha, H | 1 |
| Lee, HB | 1 |
14 other studies available for valproic acid and Alloxan Diabetes
| Article | Year |
|---|---|
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors.
Topics: Animals; Cellular Senescence; Complement C5a; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2022 |
Sox5 regulates beta-cell phenotype and is reduced in type 2 diabetes.
Topics: Animals; Calcium; Calcium Channels; Chromatin; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2017 |
Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors.
Topics: Animals; Cardiomegaly; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Cardiomy | 2018 |
Repurposing of sodium valproate in colon cancer associated with diabetes mellitus: Role of HDAC inhibition.
Topics: Animals; Anticonvulsants; Blood Glucose; Carcinoembryonic Antigen; Cell Line, Tumor; Colon; Colonic | 2018 |
Sodium valproate ameliorates memory impairment and reduces the elevated levels of apoptotic caspases in the hippocampus of diabetic mice.
Topics: Animals; Apoptosis; Caspases; Diabetes Mellitus, Experimental; Hippocampus; Male; Maze Learning; Mem | 2018 |
Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus, Experimen | 2014 |
The effect of hyperglycemia on the pharmacokinetics of valproic acid studied by high-performance liquid chromatography with electrochemical detection.
Topics: Administration, Oral; Animals; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitu | 2014 |
Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat.
Topics: Acetylation; Acute Kidney Injury; Animals; Cytokines; Diabetes Mellitus, Experimental; Diabetic Neph | 2015 |
Pancreatic response to gold nanoparticles includes decrease of oxidative stress and inflammation in autistic diabetic model.
Topics: Animals; Antioxidants; Autistic Disorder; Diabetes Mellitus, Experimental; Disease Models, Animal; F | 2015 |
Hypoglycemic, antilipidemic and antioxidant effects of valproic acid in alloxan-induced diabetic rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Calcium; Cytosol; Diabetes Mellitus, Experimental | 2015 |
Antifibrogenic role of valproic acid in streptozotocin induced diabetic rat penis.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Erectile Dysfunction; Humans; Injections, Intra | 2016 |
Valproic acid reduces insulin-resistance, fat deposition and FOXO1-mediated gluconeogenesis in type-2 diabetic rat.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gluconeogenesis; Insulin Resist | 2016 |
Valproic Acid Improves Glucose Homeostasis by Increasing Beta-Cell Proliferation, Function, and Reducing its Apoptosis through HDAC Inhibition in Juvenile Diabetic Rat.
Topics: Animals; Apoptosis; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mel | 2016 |
Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Topics: Acetylcysteine; Amides; Animals; Antioxidants; Biphenyl Compounds; Cell Line; Cell Transdifferentiat | 2009 |